HALOPERIDOL DECANOATE

Post-LOE

haloperidol decanoate

Hikma

ANDAINJECTIONINJECTABLE

Approved

Sep 1998

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

HALOPERIDOL DECANOATE (haloperidol decanoate) by Hikma is clinical pharmacology haloperidol decanoate is the long-acting form of haloperidol, an antipsychotic. Approved for schizophrenia. First approved in 1998.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Haloperidol decanoate is the long-acting form of haloperidol, an antipsychotic. The mechanism of action of haloperidol for the treatment of schizophrenia is unclear. However, its efficacy could be mediated through its activity as an antagonist at central dopamine type 2…

Indications (1)

schizophrenia

Worked on HALOPERIDOL DECANOATE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.